Summary: A new analysis of real-world hospital records identifies early indicators of which patients are most likely to benefit from Cobenfy, the first schizophrenia treatment with a novel mechanism approved in fifty years. The study finds that people with prominent negative symptoms—such as social withdrawal and low motivation—tended to gain the greatest improvements in mood and social functioning after receiving the xanomeline–trospium combination as an add-on to their existing antipsychotic regimen.
By contrast, individuals who displayed aggression or pronounced bipolar (manic) features showed little benefit, suggesting that psychosis encompasses multiple biological subtypes that respond differently to specific therapies. These findings point toward a precision psychiatry approach: matching treatments to patient symptom and biological profiles to reduce the lengthy trial-and-error process many patients endure.
Key Facts
- Negative symptoms improve most: Social withdrawal, low motivation, and reduced speech tended to respond more reliably than hallucinations or manic symptoms.
- Distinct biological subgroups suggested: Different patterns of clinical response imply that psychosis may consist of multiple, biologically distinct conditions rather than a single disorder.
- Toward precision psychiatry: Systematic tracking of symptom-specific responses could help clinicians personalize treatment and shorten time to effective therapy.
Source: Tufts University
Context: Each year, roughly 100,000 Americans experience an episode of psychosis, a serious disruption of thought and perception that can profoundly alter a person’s sense of reality. Understanding which treatments work for which patients is essential to improving outcomes and restoring functioning.
Just over a year after the approval of the first new schizophrenia medication in fifty years, researchers published an exploratory, real-world study in Nature Mental Health that examines patient responses to the drug in routine clinical settings. The paper offers early but important clues about who is most likely to benefit from the xanomeline–trospium combination, marketed as Cobenfy.
Led by Michael Halassa, professor of neuroscience at Tufts University School of Medicine, the team retrospectively analyzed electronic medical records for 49 hospitalized patients treated for schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features. All individuals received Cobenfy in addition to their usual antipsychotic medications after standard approaches failed to produce adequate symptom control.
Unlike typical antipsychotics that primarily block dopamine D2 receptors, Cobenfy targets muscarinic receptors in the nervous system. Clinical trials demonstrated efficacy compared with placebo, but clinicians and researchers have been keen to understand how the medication performs when integrated into everyday clinical care.
Halassa’s team performed a detailed post-hoc analysis. In an initial cohort of 24 patients, about 40% showed a positive response after the add-on treatment. The investigators then used hierarchical clustering and linear discriminant analysis to identify clinical features associated with response, and they replicated their findings in an independent cohort of 25 patients.
The combined analyses highlighted that prominent negative symptoms—such as social withdrawal, lack of motivation, and reduced speech—were the strongest predictors of a beneficial response. A history of stimulant use also tended to be associated with better outcomes. Conversely, the presence of intellectual disability was linked to a lower probability of improvement, although the researchers caution this observation is tentative because few patients in the sample had that diagnosis.
Responses in other symptom domains were more variable. Some patients experienced reductions in hallucinations, but these improvements were less consistent than those seen for negative symptoms. Patients displaying aggression or manic features derived minimal benefit from adding the muscarinic-targeting drug, a result that reinforces the idea of distinct psychosis subtypes that may require different pharmacological strategies.
Halassa interprets these patterns as evidence that schizophrenia and related psychoses are better viewed as a set of syndromes with diverse biological underpinnings, rather than a single uniform disease. He argues that systematic collection and analysis of symptom-level treatment responses could help clinicians choose the right medication sooner, reducing the time families spend cycling through ineffective options.
To move toward precision psychiatry, the researchers recommend designing prospective clinical trials that enroll patients according to specific cognitive or biological profiles and compare different medications in these carefully defined groups. In parallel, routine clinical practice should begin documenting which symptoms improve and which do not, treating each response pattern as valuable data to refine future treatment decisions.
Key Questions Answered:
A: The study identified early, real-world response patterns showing which patients tend to improve when Cobenfy is added to standard antipsychotic treatment, emphasizing symptom profiles associated with benefit.
A: Patients with prominent negative symptoms—social withdrawal, low motivation, and reduced speech—showed the most consistent improvements in mood, engagement, and day-to-day functioning.
A: Individuals with aggression, manic features, or intellectual disabilities showed minimal benefit in this analysis, suggesting the need for tailored approaches for different psychosis subgroups.
About this psychopharmacology and schizophrenia research news
Author: Genevieve Rajewski
Source: Tufts University
Contact: Genevieve Rajewski – Tufts University
Image: The image is credited to Neuroscience News
Original Research: Closed access.
“Preliminary real-world predictors of response to muscarinic targeting in psychosis” by Michael Halassa et al. Nature Mental Health
Abstract
Preliminary real-world predictors of response to muscarinic targeting in psychosis
Xanomeline/trospium (Cobenfy) was recently approved by the US Food and Drug Administration for the treatment of adults with schizophrenia.
Despite encouraging results from randomized placebo-controlled trials, evidence about how the medication performs in routine clinical settings remains limited.
This study reports a post-hoc analysis of inpatient medical records after Cobenfy was added to existing antipsychotic regimens. In an initial cohort of 24 patients, approximately 40% experienced a positive clinical response.
Using hierarchical clustering and linear discriminant analysis to identify predictive clinical features, the investigators found that negative symptoms and prior stimulant use were the strongest predictors of a favorable response, while intellectual disability predicted poorer outcomes. These associations were independently replicated in a second cohort of 25 patients.
Overall, the findings support the concept of biologically distinct psychosis subgroups and underscore the need for further research into the underlying biological mechanisms and for prospective trials that match treatments to patient-specific profiles.